This Study Aims to Use Convalescent Plasma as Experimental Treatment in Critically Ill Patients With Covid-19

• Status: Recruiting
• Trial end date: 2021-06-25
• Target enrollment: 36
• Participant gender: All

Summary

This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hospital de Infecciosas Francisco Javier Muniz

Criteria

Inclusion Criteria:

• Older than 18 years.

• Patient with Covid-19 confirmed with nuclear acid testing

• Critically ill patients with Covid-19 on mechanical ventilation. Potencially critically ill patients with Covid-19 (with acute respiratory distress syndrome, septic shock and/or multiple organ failure).

• Diagnosed with acute respiratory distress syndrome.

• Informed consent.

Exclusion Criteria:

• No consent.

• Symptoms for a period longer than 20 days.

• Not detectable by acid nuclear testing within 48 hours prior to elegibility.

• Descompensated congestive heart failure, in which receiving 500ml of intrasvascular volume signifies a life risk.

• History of severe adverse events or anaphylaxis to plasma components